Avery Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.15 M
as on 16-11-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 16-11-2024
- Revenue 4960.56%
(FY 2023)
- Profit -239.31%
(FY 2023)
- Ebitda -136.04%
(FY 2023)
- Net Worth -139.54%
(FY 2023)
- Total Assets 7.47%
(FY 2023)
About Avery Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 7.15 M.
The company currently has active open charges totaling ₹3.00 Cr.
Shilpan Patel and Neil Patel serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC295476
- Company No.
295476
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2017
- Date of AGM
02 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Avery Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpan Patel  | Director | 29-May-2017 | Current |
| Neil Patel | Director | 29-May-2017 | Current |
Financial Performance and Corporate Structure Insights of Avery Pharmaceuticals.
Avery Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 4960.56% increase. The company also saw a substantial fall in profitability, with a 239.31% decrease in profit. The company's net worth observed a substantial decline by a decrease of 139.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avery Pharmaceuticals?
In 2023, Avery Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Arrow Agri-Tech Private LimitedActive 14 years 3 months
Shilpan Patel and Neil Patel are mutual person
- Arrow Business Advisory Private LimitedActive 34 years 9 months
Shilpan Patel and Neil Patel are mutual person
- Lq Arrow Security Products (India) Private LimitedActive 7 years 3 months
Shilpan Patel is a mutual person
Arrow Secure Technology Private LimitedActive 18 years 2 monthsShilpan Patel and Neil Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 May 2019 | ₹3.00 Cr | Open |
How Many Employees Work at Avery Pharmaceuticals?
Avery Pharmaceuticals has a workforce of 41 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avery Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avery Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
